ReviewJournal of pain research2024
Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options.
Review in Journal of pain research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Efficacy and Safety of Ion Channel Modulators in Painful Diabetic Neuropathy.Diabetes, obesity & metabolism · 2026Pooled it
- Spinal Cord Stimulation for Painful Diabetic Neuropathy: A Systematic Review and Meta-Analysis of High- and Low-Frequency Modalities.Pain research & management · 2026Pooled it
- Pregabalin and duloxetine combination for painful diabetic neuropathy: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Procedural Optimization of Capsaicin 8% Patch Therapy Using Ultrasound-Guided Bilateral Ankle Nerve Block in Painful Diabetic Peripheral Neuropathy: A Retrospective Comparative Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Innovative strategies for diabetic peripheral neuropathy: From clinical management to emerging bioengineering solutions.Bioactive materials · 2026Review
- Lymphovenous Bypass as an Adjunct to Standard Care for Diabetic Peripheral Neuropathy: Protocol for a Randomized Assessor-Blinded Superiority Trial.JMIR research protocols · 2026Article
- PRMT6 inhibition or deficiency attenuates diabetic neuropathic pain in male mice and is associated with reduced spinal neuroinflammation, microgliosis, and altered p53-p21 signaling.Journal of neuroinflammation · 2026Article
- Mechanisms of Action of Low-Frequency Pulsed Magnetic Fields in Pain Control.Bioengineering (Basel, Switzerland) · 2026Review
- [Medium- and long-term clinical efficacy of tibial transverse transport surgery in the treatment of diabetic foot ulcers].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Article
- The role of perioperative tapentadol in inguinal hernia repair: Implications for acute analgesia and chronic postoperative pain - a narrative review.Hernia : the journal of hernias and abdominal wall surgery · 2026Review
- Practices and attitudes of Thai community pharmacists in managing diabetic peripheral neuropathy using neurotropic B vitamins.Journal of pharmaceutical policy and practice · 2026Article
- Transcriptomic and molecular evidence for baclofen-associated modulation of inhibitory synaptic and neuroinflammatory pathways in diabetic neuropathic pain.Frontiers in pharmacology · 2026Article
- A Comparative Cost-Consequence Analysis of Spinal Cord Stimulation and Magnetic Peripheral Nerve Stimulation for the Treatment of Painful Diabetic Peripheral Neuropathy in an Integrated Health System.Journal of pain research · 2026Article
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Oxymatrine alleviates symptoms in high-fat diet and STZ-induced SD rats with painful diabetic neuropathy by reducing inflammation and oxidative stress.Frontiers in immunology · 2026Article
- TLR4 deletion reduces small fiber sensory abnormalities and nerve degeneration in diabetic male mice.Neuroscience · 2025Article
- A Pragmatic Approach to Improving Management and Patient Flow for Painful Diabetic Neuropathy in UK Primary Care.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Bibliometric Analysis: Insights Into the Podiatric Medicine Landscape of Diabetic Sensory Peripheral Neuropathy and Genomics.Journal of foot and ankle research · 2025Article
- Palmitoylethanolamide as a Supplement: The Importance of Dose-Dependent Effects for Improving Nervous Tissue Health in an In Vitro Model.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Painful diabetic peripheral neuropathy (DPN) is a highly prevalent and disabling complication of diabetes that is often misdiagnosed and undertreated. The management of painful DPN involves treating its underlying cause via lifestyle modifications and intensive glucose control, targeting its pathogenesis, and providing symptomatic pain relief, thereby improving patient function and health-related quality of life. Four pharmacologic options are currently approved by the US Food and Drug Administration (FDA) to treat painful DPN. These include three oral medications (duloxetine, pregabalin, and tapentadol extended release) and one topical agent (capsaicin 8% topical system). More recently, the FDA approved several spinal cord stimulation (SCS) devices to treat refractory painful DPN. Although not FDA-approved specifically to treat painful DPN, tricyclic antidepressants, serotonin/norepinephrine reuptake inhibitors, gabapentinoids, and sodium channel blockers are common first-line oral options in clinical practice. Other strategies may be used as part of individualized comprehensive pain management plans. This article provides an overview of the most recent US guidelines for managing painful DPN, with a focus on the two most recently approved treatment options (SCS and capsaicin 8% topical system), as well as evidence for using FDA-approved and guideline-supported drugs and devices. Also discussed are unmet needs for this patient population, and evidence for potential future treatments for painful DPN, including drugs with novel mechanisms of action, electrical stimulation devices, and nutraceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.